Resolution and concordance in dissecting the compound IJP by King, BF
PERSPECTIVES 2012
1
Resolution and concordance in dissecting the compound IJP
by
Brian F. King
University College London (UCL)
Neuroscience, Physiology & Pharmacology (NPP)
Royal Free Campus, Rowland Hill Street
London NW3 2PF, UK
Email: b.king@ucl.ac.uk
PERSPECTIVES 2012
2
The current issue of The Journal of Physiology contains two outstanding papers describing
the pharmacological dissection of the compound IJP (Gallego et al. 2012; Hwang et al.
2012). Both papers show that the inhibitory junction potential (IJP) can be broken down to
an initial purinergic component, followed by a later nitrergic component, in the circular
muscle of murine colon. Furthermore, they show that the metabotropic P2Y1 receptor is the
sole purinoceptor subtype mediating the initial component of the compound IJP, based on
the outcome of experiments using P2Y1-selective antagonists and P2Y1-deficient tissues.
Additionally, they describe the consequence of P2Y1 receptor deletion on patterns of
motility at rest and during stimulation of motor nerves. It is rare that two papers submitted
to The Journal should contain identical findings and reach identical conclusions. Thus I
speak of “resolution” and “concordance” in the title of this perspective, to signify the positive
outcome of these studies and acknowledge a consensus on mechanistic detail.
Dissection of the IJP began with the proposal that “ATP or a related nucleotide” is released
by the inhibitory motoneurons in the gut (Burnstock et al. 1970). Accumulated evidence
shows that the activation of a P2Y receptor subtype evokes an apamin-sensitive, calcium-
dependent potassium current (via SK channels) to rapidly hyperpolarise smooth muscle. In
turn, this nucleotide-evoked hyperpolarisation reduces the probability of opening of
L-type Ca2+-channels, thereby reducing Ca2+-influx and intracellular Ca2+-levels and so
promoting the active relaxation of smooth muscle. The purinoceptor concept for active
relaxation of smooth muscle has become part of mainstream thought, although this concept
was not wholly embraced in the past, and for good reasons, by myself and former
colleagues in Glasgow (viz. Bowman, Creed, Gibson, Gillespie, Martin, McGrath, Muir etc.).
Each of us had reported much slower non-purinergic IJPs and/or active relaxations in the
rat and rabbit anococcygeus and/or rabbit rectococcygeus, the so-called accessory
muscles of defecation (for example, see: King et al. 1977). In these two tissues, evidence
PERSPECTIVES 2012
3
was in favour of another inhibitory neurotransmitter released by the pelvic nerves (or “nervi
erigentes”), the same nerves that bring about tumescence and penile erection. This
inhibitory neurotransmitter was antagonised by haemoglobin and was eventually shown to
be nitric oxide (NO). Ultimately it was proposed that released ATP accounts only for rapid
IJPs whereas a mixture of NO and VIP (or the structurally related peptide, PACAP) may
account for slower IJPs, particularly in smooth muscle preparations pretreated with apamin
(to remove the fast IJP) and/or Substance P (to remove the slow EJP) (He and Goyal,
1993) (see Figure 1). The slow IJP is reduced and/or abolished by the nNOS inhibitor,
L-NNA (L-NG-NitroArginine), a procedure which has been revisited in the two focus papers
of this perspective.
As the synaptic physiology of the compound IJP was unfolding, complementary studies led
to the isolation of a single cDNA (clone 803) in chick brain. Clone 803 is present in the
gastrointestinal tract and, subsequently, this cDNA was found to encode a G protein-
coupled ATP receptor which we called P2Y1 (Webb et al. 1993). Recombinant P2Y1
receptors and ATP-mediated relaxations of gut smooth muscle were antagonised by
pyridylisatogen tosylate (PIT) (King et al. 1996), a substance first used to differentiate
between ATP- and adenosine-mediated inhibitory responses in the gut. PIT is now known
to be a selective antagonist of P2Y1 receptors, without effect at P2Y2, P2Y4, P2Y6, P2Y11 or
P2Y12 receptors (Gao et al. 2004). A better series of highly potent P2Y1 antagonists have
since been discovered, based on: the adenosine bisphosphate scaffold, substitution of the
ribose moiety by N-methanacarbo pseudosugars, and modifications at the C2 and N6
positions on the purine moiety. This series includes MRS2179 and MRS2279 (Nandanan
et al. 2000) as well as MRS2500 (Hechler et al. 2006). ATP responses and purinergic IJPs
are potently antagonised by these compounds, a procedure again revisited by the two focus
papers of this perspective.
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The last key element to the two focus papers is the availability of homozygotic P2Y1-/- mice,
which were genetically engineered in the first instance to investigate the role of P2Y1 (Fabre
et al.1999) and thereafter P2X1 receptors (Fabre et al. 2001) in nucleotide mediated
thromboembolism of blood platelets. Up to the present time, wild-type and P2Y1-/- mice
have been used side by side to compare the activity of P2Y1 antagonists (such as
MRS2179, MRS2279, MRS2500) and P2Y1 agonists (ADP, MRS2365 and -NAD) and to
examine the facilitatory role of the P2Y1 receptor in thromboembolism and vascular
disease. It is therefore a radical departure from script to see P2Y1-/- mice and these
pharmacological agents used now in investigations of the compound IJP.
So armed and prepared, the authors of the two current focus papers have provided us with
a wealth of information on the roles of purinergic and nitrergic transmission in the gut. Their
studies focussed on the colon, principally an organ of storage involved in the periodic
elimination of waste. These two focus papers show that ATP and NO are released tonically
by inhibitory nerves and, alongside adrenergic tone, contribute to controlling the colon.
Each appears to serve a different role; adrenergic tone controls motoneurons in the ENS;
nitrergic tone controls the membrane potential; purinergic tone controls the amplitude of
excitatory responses. One of the focus papers also reports a profound disturbance in
colonic transit in P2Y1-deficient mice (Hwang et al. 2012).
The authors have raised two important, if controversial, issues. Both papers discuss the
possibility that -NAD, rather than ATP, may be the cognate ligand for the P2Y1 receptor.
This is not a new proposal, but certainly one that will require further investigation. Both
papers also discuss the possibility that P2Y1 receptors mediating the purinergic IJP may be
located in the fibroblast-like (PDGRF+) cells and not smooth muscle cells, and this too will
require further investigation. Yet, both papers serve to stimulate the reader and challenge
their audience to consider new concepts. For this reason, these are outstanding papers.
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Lastly, readers must look to see which of these new discoveries can be applied to organs of
storage such as the stomach or caecum. Both are heavily invested with inhibitory nerves
which, for example, elicit fast IJPs in antral circular muscle to reset the slow wave firing
frequency (King, 1994) or elicit fast and slow purinergic relaxations in longitudinal muscle of
taenia to modify the storage capacity of the caecum (King & Townsend-Nicholson, 2008).
We must be grateful to the authors of these two focus papers for launching a new era of
gastrointestinal physiology, where there will be abundant opportunities for further research
and which may help resolve currently irretractable diseases of gastrointestinal storage and
transit.
Figure 1
Electrical stimulation of myenteric motoneurons produces a mixture of inhibitory and excitatory junction
potentials in many types of gut smooth muscle. The initial fast hyperpolarization is a purinergic IJP and
blocked by apamin (10-7 M; SK channel inhibitor). The secondary hyperpolarization is the nitrergic IJP
although, in some tissues, a small component may be mediated by VIP. The late, slow depolarization is a
peptidergic EJP produced by neurokinins, and a component is desensitised by Substance P. These
records (King: unpublished data) were made from circular muscle of guinea-pig ileum paralyzed by
atropine (10-6 M) and nicardipine (10-6 M). Analyses of synaptic events are based on data from Bywater and
Taylor (1986).
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